Amgen Inc.

Thousand Oaks, CA

UEI
D92HARF1LKA9
CAGE
0JVZ6
Primary NAICS
325412 Pharmaceutical Preparation Manufacturing
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Manufacturer of Goods
Entity structure
Corporate Entity (Not Tax Exempt)
Corporate family
SAM.gov registration date
Physical address
1 Amgen Center Dr, Thousand Oaks, CA 91320, USA
Website
amgen.com
Founded
1980
Employees
10K-50K
Estimated annual revenue
$10B+
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $2,276,291
FY2024 $0
FY2023 $7,290,924

Contract awards

Latest 5 listed here. See the rest on GovTribe.

Similar vendors

About the company

Amgen Inc. is a prominent biopharmaceutical company that has been registered to receive awards from the U.S. federal government since May 7, 2001. As a for-profit organization and manufacturer of goods, Amgen primarily provides pharmaceutical products and services to various government agencies. The company has secured federal contract awards for the development of medical countermeasures, including vaccines and therapeutics, as well as the supply of influenza vaccines. Amgen's expertise in biotechnology and its focus on developing innovative medicines for serious illnesses have positioned it as a valuable partner for government agencies seeking advanced medical solutions.

Recent federal contract awards to Amgen Inc. and its subsidiaries demonstrate the company's involvement in critical health-related projects. A significant contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) tasked Amgen with developing an NPLATE administration kit for the treatment of approved indications, including Acute Radiation Syndrome (ARS). This cost-sharing contract, valued at $7,290,923.50, extends through August 2026. Additionally, Amgen USA Inc., a subsidiary, has been contracted to supply influenza vaccines to various government entities. The Department of Veterans Affairs awarded a $74,669.20 contract for AFLURIA QUADRIVALENT pre-filled syringes, while the Department of Justice Bureau of Prisons engaged Amgen to provide flu shots for staff at the Federal Correctional Institution Terminal Island in California through multiple delivery orders. These contracts highlight Amgen's role in supporting public health initiatives and government vaccination programs across different sectors, including veterans' health and correctional facilities. No set-aside designations were identified in these recent awards, indicating that Amgen competes for these contracts in the open market.

Quick answers

Is Amgen Inc. registered in SAM.gov?

Yes. Amgen Inc.'s SAM.gov registration is active through March 19, 2027.

How much has Amgen Inc. received in federal contracts?

Federal contracts obligated $2,276,291 to Amgen Inc. in fiscal year 2025 and $9,567,215 in fiscal years 2023 through 2027.

What is Amgen Inc.'s most recent federal award?

Amgen Inc.'s most recent federal contract award is Nplate administration kit development for the treatment of approved indications, including acute radiation syndrome… (75A50123C00040), from Office of the Assistant Secretary for Preparedness and Response, on August 28, 2023.

On GovTribe

See Amgen Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors